Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Qiagen ( (QGEN) ).
QIAGEN N.V. disclosed a manager transaction involving supervisory board member Stephen Rusckowski, who received 5,990 common shares through the release of an equivalent number of restricted stock units granted in February 2025. The transaction, executed outside a trading venue on February 28, 2026, reflects routine equity-based compensation and marginally increases insider share ownership, but does not represent an open-market purchase or sale and is unlikely to materially affect the company’s capital structure or market positioning.
The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. is a Netherlands-based life sciences company that develops and supplies sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its shares are listed on multiple European exchanges as well as the NYSE and Swiss markets, giving it broad access to international investors.
Average Trading Volume: 2,173,009
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.1B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.